ORD India – Be Aware And Preventive

In 2012, Ethan Perlstein challenged the academic status quo. Now as CEO of the start-up Perlara, can he do the same for the biotech industry?
In 2012, molecular biologist Ethan Perlstein very publicly stepped off the academic treadmill. In his view, the system was raising more young researchers than it could absorb, driving people into an increasingly long training cycle. Perlstein, at the...

Today, more than 5,000 diseases are catalogued as “rare” by the scientific community, so long as they affect small sections of population. The drugs used for the treatment of rare diseases are known as orphan drugs. An orphan drug is a pharmaceutical...

Health experts Wednesday highlighted the need for an immediate call-to-action for the implementation of the National Policy for Treatment of Rare Diseases, stating that the patients were suffering and losing out on time.
The policy was approved by the Union Health Ministry in May last year, but it is yet to see light of the day....

Medical experts say India also needs an orphan drug policy to provide incentives to pharmaceutical companies to innovate and manufacture drugs for rare diseases
https://www.business-standard.com/article/economy-policy/after-new-rare-diseases-policy-govt-incentives-needed-for-finding-cures-117113000229_1.html...